Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

141 results about "Coronary flow" patented technology

The resting coronary blood flow is ∼250 ml min −1 (0.8 ml min −1 g −1 of heart muscle); this represents 5% of cardiac output. Ischaemia results when oxygen demand outstrips supply. Blood flow to the heart occurs mainly during diastole. Coronary blood flow is mainly determined by local oxygen demand.

Method for computing FFR<CT> (fractional flow reserve <computed tomography>) on basis of personalized coronary artery branch blood flow volumes

The invention discloses a method for computing FFR<CT> (fractional flow reserve <computed tomography>) on the basis of personalized coronary artery branch blood flow volumes, and belongs to the field of biomechanics and haemodynamics. The method includes clinically acquiring physiological parameters of cardiac muscle masses, heart rates, blood pressures and the like of patients and establishing coronary blood flow volume computing empirical formulas on the basis of allometric growth laws; rebuilding three-dimensional geometric models of coronary arteries on the basis of CT images of the coronary arteries of the patients, acquiring the volumes of blood vessels of branches of the coronary arteries and the vessel diameters of the various branches and acquiring split ratios of the various branches on the basis of the volumes of the blood vessels of the branches and the Poiseuille law; combining the coronary blood flow volumes of the patients and the split ratios of the various branches with one another, acquiring the blood flow volumes of the various branches of the coronary arteries by means of computing and solving the FFR<CT> of the coronary arteries of the patients by the aid of the blood flow volumes of the various branches of the coronary arteries. The blood flow volumes of the various branches of the coronary arteries are used as coronary haemodynamics computing boundary conditions. The method has the advantages that FFR of the coronary arteries of human bodies can be noninvasively computed, simulation results can be similar to real blood flow states under the condition of the maximum congestion states of the coronary arteries of the patients owing to personalized coronary flow boundaries, and accordingly the coronary artery FFR<CT> computing accuracy can be improved.
Owner:BEIJING UNIV OF TECH

Heterophylly falsestarwort root health tea and preparation method thereof

The invention discloses a heterophylly falsestarwort root health tea and a preparation method thereof, and the health tea is prepared by the following raw materials by weight: 40-60% of heterophylly falsestarwort root powder, 15-20% of medlar, 10-15% of arillus longan, 15-25% of osmanthus fragrans. Heterophylly falsestarwort root contains abundant polysaccharides, a plurality of essential amino acids, a plurality of trace elements and the like, is mainly used to treat spleen deficiency and tireness, anorexia, weakness after diseases, qi and yin deficiency, spontaneous perspiration and hydrodipsia, lung dryness and dry cough, palpitation and insomnia, deficiency heat and hyperidrosis; medlar has the efficacy of nourishing liver and kidney, nourishing liver and improving eyesight; arillus longan contains protein, fat, carbohydrates, organic acids, crude fibers, and a plurality of vitamins and mineral matter, and has the effects of improving body immunity, inhibiting tumor cells, reducing blood lipid, increasing blood flow of coronary artery, and enhancing body diathesis; osmanthus fragrans has the efficacy of relieving cough and resolving phlegm, preserving health and moistening lung. The health tea of the invention has a reasonable formula and synergistic effects, not only can be used as a tea drink, but also has nourishing and life-prolonging effects.
Owner:食品行业生产力促进中心

Mixed oil and fat capable of preventing and treating cardiovascular diseases

The invention discloses mixed oil and fat capable of preventing and treating cardiovascular diseases. The mixed oil and fat consists of the following raw materials in parts by weight: 1-10 parts of fish oil, 1-10 parts of perilla herb oil, 1-10 parts of pomegranate seed oil, 12-80 parts of vegetable oil and fat, 0.9-1.5 parts of a stabilizing agent and 0.4-0.6 part of a fragrance additive, whereinthe weight ratio of EPA to DHA in the fish oil is (6-9) to 1, and the weight of the EPA and the DHA is 50-95% of that of the fish oil. The mixed oil and fat disclosed by the invention has notable treatment effects of preventing and treating the cardiovascular diseases; through scientific blending, the mixed oil and fat contains EPA, flavone, oryzanol, sterol, punicic acid, VE, phytosterol and thelike, has good treatment effects on heart and cerebral vessels, can regulate fat metabolism, can prevent and treat arteriosclerosis, can reduce blood cholesterol and blood viscosity, can restrain platelet aggregation and can improve blood circulation; and the mixed oil and fat can have the effects of reducing low-density protein, increasing high-density lipoprotein, recovering the elasticity of blood vessels, increasing the blood flow of coronary arteries, and preventing and treating arteriosclerosis and high blood pressure, so that the purposes of preventing and / or treating the cardiovascular diseases and particularly treating coronary heart diseases and the high blood pressure can be realized.
Owner:SHANDONG ZHUSHI PHARMA GRP CO LTD

Medicinal composition for treating angina pectoris of coronary heart disease and application thereof

The invention discloses a medicinal composition for treating angina pectoris of coronary heart disease. The medicinal composition consists of the following raw material medicines: cassia twig, officinal magnolia bark, humifuse euphorbia herb, Mongolian dandelion herb, cape jasmine fruit, szechuan lovage rhizome, diverse wormwood herb, processed pinellia tuber, bitter orange, rhizome of swordlike atractylodes, root of lobed kudzuvine, myrrh, arisaema consanguineum schott, cassia seed, costustoot, thinleaf milkwort root-bark, motherwort herb, silktree albizzia bark, safflower, long pepper, szechwan chinaberry fruit, fortune eupatorium herb, panax notoginseng, bezoar, snakegourd fruit, nutgrass galingale rhizome, Chinese thorowax root, mulberry fruit, lychee seeds, lucid ganoderma, dragon's blood, grassleaf sweelflag rhizome, licorice root and cyrtomium rhizome. By adopting the medicinal composition disclosed by the invention, the attack times of angina pectoris of coronary heart disease can be effectively reduced, the attack duration of angina pectoris can be shortened, the occurrence of myocardial infarction can be avoided, sudden death caused by angina pectoris can be avoided, and adverse reactions cannot be caused; and the medicinal composition is accurate in curative effect and small in toxic or side effect, ensures that the cardiac stroke volume and cardiac output can be increased, cardiac indexes can be increased, the cardiac pumping functions can be enhanced, the ventricular diastolic functions and arterial compliance can be improved, coronary arteries can be expanded and the blood flow volume of the coronary arteries can be increased, and has significant curative effects on the aspect of treating angina pectoris of coronary heart disease.
Owner:QINGDAO MUNICIPAL HOSPITAL

Generation of vascularized human heart tissue and uses thereof

The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+ / NKX2.5− / KDR−. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and / or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and / or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors.
Owner:THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products